Author: Jorge Ruiz-Medrano (Spain)
Co-authors: Elena Almazan-Alonso, Mariluz Puertas Ruiz-Falcó, Marina Fernandez Jimenez, Lucía Gonzalez-Buendía, Pablo Garcia-Pavia, Jose María Ruiz-Moreno
Purpose
Patients suffering from Transthyretin (TTR) amyloidosis have been described to show ocular alterations. The objective of this study is to present the relationship between these ocular manifestations and the systemic disorders associated with amyloidosis.
Setting/Venue
Puerta de Hierro University Hospital, Majadahonda, Madrid (Spain).
Methods
Cross-sectional, non-interventional study including 52 eyes from 26 patients with hATTR amyloidosis under follow-up by Cardiology and Ophthalmology Departments. A complete ophthalmological examination was performed including: Best-corrected visual acuity (BCVA), axial length measurement, slit-lamp anterior segment examination, pachymetry, endothelial count, funduscopy, fundus photography, optical coherence tomography (OCT), OCT angiography (OCTA), fundus autofluorescence (FAF), infrared reflectance (IR) and fluorescein angiography (FA) in the cases that showed alterations on OCTA. In addition, a retrospective review of clinical records to describe the systemic hATTR involvement was carried out.
Results
18 out of 52 eyes (34.6%) showed signs of ocular affectation, been women more likely to have their eyes compromised (n=12/18; p<;0,05). Most of the affected eyes showed signs of ocular amyloidosis at the posterior pole, been the most frequent ocular manifestation the vitreous deposits (34,61 %, 18/52). Among other signs, highlight the presence of amyloid deposits in crystalline lens (n=4/18), vascular deposits (n= 3/18) and retinal parenchyma (n=10/18). The mean time from diagnosis to ophthalmological assessment was 29 months (Range 0-194). Regarding systemic hATTR involvement, 84,61 % (22/26) patients showed neurological amyloid related manifestations, 84,61 % (22/26) cardiac, 45,4% (10/22) digestive and only 3,84% (1/6) showed renal involvement. 100% of the patients with ocular amyloidosis presented neurological and cardiac involvement simultaneously. Patients under treatment had mild cardiac pathology in contrast to those without treatment (p<;0,05); nevertheless, there were not statistically significant differences regarding ocular or cardiac involvement between treatments (p>0.05). Cardiac involvement was related not only with ocular involvement but also with worse visual acuity (p<;0,05). Mutations found included: Vall30Met (30.8 %), Glu89Lys (26.9%), Vall22Ile (30, 8%), Ser43Asn (11, 5%). None of them presented statistical differences in relation with ophthalmological involvement (p>;0,05).
Conlusions
Patients suffering from familial TTR amyloidosis should be subject to a complete ophthalmological examination, specifically those with cardiac involvement, due to their willingness to suffer from ophthalmological complications that may compromise their visual acuity.
Financial Disclosure
none
Comments
-